- Home
- / OBI Pharma
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
OBI Pharma financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
NT$65.2
2024-10-29
Market Capitalization
NT$15.2 B
2024-10-29
Revenue
NT$41.5 M
FY, 2023
CreditSafe Score
?
Score changed on Apr 24, 2025
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| TWD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 |
|---|---|---|---|---|---|---|
| Revenue | 13.3M | 5.6M | 140.9M | 18.8M | 4.7M | 41.5M |
| Cost of goods sold | 5.3M | 12.4M | 6.5M | 44.4M | 44.9M | 115.0M |
| Gross profit | 10.0M | (4.8M) | 142.8M | (16.7M) | (36.0M) | (63.8M) |
| Gross profit margin, % | 74.7% | -86.0% | 101.3% | -89.2% | -765.0% | -153.5% |
| Operating expense total | 1.3B | 1.4B | 1.4B | 1.5B | 1.8B | 1.8B |
| Depreciation and amortization | 122.6M | 213.9M | 231.8M | 216.3M | 246.6M | 254.9M |
| EBITDA | (1.3B) | (1.4B) | (1.2B) | (1.5B) | (1.9B) | (2.0B) |
| EBITDA margin, % | -9769.5% | -24363.2% | -870.0% | -7942.1% | -39737.8% | -4800.9% |
| EBIT | (1.4B) | (1.7B) | (1.4B) | (1.7B) | (2.1B) | (2.3B) |
| EBIT margin, % | -10688.9% | -30834.9% | -1000.0% | -9071.2% | -44994.9% | -5423.8% |
| Interest income | 89.0M | 93.4M | 43.4M | 6.5M | 49.9M | 93.0M |
| Interest expense | 1.7M | 3.9M | 4.2M | 3.8M | 4.0M | 7.9M |
| Pre tax profit | (1.3B) | (1.7B) | (1.5B) | (1.7B) | (1.9B) | (1.3B) |
| Income tax expense | (6.3M) | (5.6M) | (3.8M) | (24.4M) | (17.8M) | (9.6M) |
| Net Income | (1.2B) | (1.7B) | (1.5B) | (1.7B) | (1.9B) | (1.3B) |